Clinical Trial Update: Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 study update evaluating upfront CART-BCMA with or without huCART19 in high-risk multiple myeloma. The trial status is ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CART-BCMA
• huCART19

Snippet

Sponsor: University of Pennsylvania | Conditions: Multiple Myeloma | Phase 1 | Status: ACTIVE_NOT_RECRUITING